Literature DB >> 11109060

Sweat analysis proficiency testing for cystic fibrosis.

V A LeGrys1.   

Abstract

The purpose of this report is to describe the College of American Pathologists sweat testing (SW) proficiency testing program for cystic fibrosis, to evaluate its impact on test performance, and to describe the current practice of sweat testing in North America. The study analyzed participant summary reports of the SW survey from 1994-1998 (SW 94-98) and Proficiency Testing Exception Summary reports from 1996-1998. The data collected from SW 94-98 allowed for the assessment of trends and/or changes in sweat testing practices. The data collected from SW-A 1998 provided a profile of current practices in sweat testing. While the overall performance on the SW survey is encouraging, the program has identified areas of concern. The number of poorly performing laboratories are few in number, yet if the reported results had been patient specimens, the clinical implications would have been significant. The SW survey is meeting its goal of providing feedback to institutions on their performance of sweat analysis and providing educational materials on the total testing process in an effort to improve the quality of sweat testing. Significant changes in practice have occurred in many institutions performing sweat tests, and a greater awareness of analyte identification has resulted. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11109060     DOI: 10.1002/1099-0496(200012)30:6<476::aid-ppul7>3.0.co;2-o

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  6 in total

1.  A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.

Authors:  Bonnie W Ramsey; Jane Davies; N Gerard McElvaney; Elizabeth Tullis; Scott C Bell; Pavel Dřevínek; Matthias Griese; Edward F McKone; Claire E Wainwright; Michael W Konstan; Richard Moss; Felix Ratjen; Isabelle Sermet-Gaudelus; Steven M Rowe; Qunming Dong; Sally Rodriguez; Karl Yen; Claudia Ordoñez; J Stuart Elborn
Journal:  N Engl J Med       Date:  2011-11-03       Impact factor: 91.245

2.  Sweat test and cystic fibrosis: overview of test performance at public and private centers in the state of São Paulo, Brazil.

Authors:  Maria Fátima Servidoni; Carla Cristina Souza Gomez; Fernando Augusto Lima Marson; Adyléia Aparecida Dalbo Contrera Toro; Maria Ângela Gonçalves de Oliveira Ribeiro; José Dirceu Ribeiro; Antônio Fernando Ribeiro
Journal:  J Bras Pneumol       Date:  2017 Mar-Apr       Impact factor: 2.624

3.  Citrate-based fluorescent materials for low-cost chloride sensing in the diagnosis of Cystic Fibrosis.

Authors:  Jimin P Kim; Zhiwei Xie; Michael Creer; Zhiwen Liu; Jian Yang
Journal:  Chem Sci       Date:  2016-08-30       Impact factor: 9.825

4.  Evaluation of continuous constant current and continuous pulsed current in sweat induction for cystic fibrosis diagnosis.

Authors:  Carla Cristina Souza Gomez; Fernando Augusto Lima Marson; Maria Fátima Servidoni; Antônio Fernando Ribeiro; Maria Ângela Gonçalves Oliveira Ribeiro; Veruska Acioli Lopes Gama; Eduardo Tavares Costa; José Dirceu Ribeiro; Francisco Ubaldo Vieira Junior
Journal:  BMC Pulm Med       Date:  2018-09-14       Impact factor: 3.317

5.  Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D-CFTR mutation.

Authors:  Steven M Rowe; Bo Liu; Aubrey Hill; Heather Hathorne; Morty Cohen; John R Beamer; Frank J Accurso; Qunming Dong; Claudia L Ordoñez; Anne J Stone; Eric R Olson; John P Clancy
Journal:  PLoS One       Date:  2013-07-26       Impact factor: 3.240

6.  The Italian External Quality Assessment Program for Cystic Fibrosis Sweat Chloride Test: Does Active Participation Improve the Quality?

Authors:  Marco Salvatore; Annalisa Amato; Giovanna Floridia; Federica Censi; Gianluca Ferrari; Fabrizio Tosto; Rita Padoan; Valeria Raia; Natalia Cirilli; Giuseppe Castaldo; Ettore Capoluongo; Ubaldo Caruso; Carlo Corbetta; Domenica Taruscio
Journal:  Int J Environ Res Public Health       Date:  2020-05-04       Impact factor: 3.390

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.